Dimemorphan — Competitive Intelligence Brief

Dimemorphan (DIMEMORFAN) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: dimemorfan. Area: Pain.

phase 2 dimemorfan Sigma non-opioid intracellular receptor 1 Pain Small molecule

Target snapshot

Dimemorphan (DIMEMORFAN). Dimemorfan works by activating opioid receptors in the brain to reduce pain perception.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Dimemorphan TARGET	DIMEMORFAN		phase 2	dimemorfan	Sigma non-opioid intracellular receptor 1
Aricept	DONEPEZIL	Eisai	marketed	Cholinesterase Inhibitor	Sigma non-opioid intracellular receptor 1	1996-01-01
Naftin	NAFTIFINE	Legacy Pharma	marketed	Allylamine Antifungal	Sigma non-opioid intracellular receptor 1	1988-01-01
Cefaprin	cefapirin	Bristol-Myers Squibb	marketed	cefapirin	Sigma non-opioid intracellular receptor 1	1974-01-01
Gocovri	AMANTADINE	Endo	marketed	Influenza A M2 Protein Inhibitor	Sigma non-opioid intracellular receptor 1	1968-01-01
Aralen	CHLOROQUINE	Sanofi	marketed	Antimalarial	Sigma non-opioid intracellular receptor 1	1949-01-01
Pentoxiverine	pentoxyverine		marketed	Central Nervous System Stimulant [EPC]	Sigma non-opioid intracellular receptor 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (dimemorfan class)

1. · 1 drug in this class